Mechanisms of EREG incryptococcal traversal of the blood-brain barrier

Abstract

Abstract: Objective To determine the expression level of EREG in the blood-brain barrier infected by Cryptococcus neoformans and to explore the role of EREG crossing the blood-brain barrier. Methods To construct the model of blood brain barrier in vitro by using Cryptococcus neoformans and Transwell chamber, and PBS was used as the control group. According to the time of Cryptococcus infection, divided into three groups: 3 h, 6 h and 12 h. The changes of the adhesion and penetration ability of Cryptococcus to the blood-brain barrier were detected by detecting the transmembrane resistance of single cells in the upper chamber of the Transwell and the suspension coating in the lower chamber of the Transwell at different time of infection, and the expression level of EREG in vascular endothelial cells during the process was detected. Results The expression of EREG was significantly increased and positively correlated with the time of infection during the course of cryptococcal infection with microvascular endothelial cells. Conclusion These results indicated that the ability of Cryptococcus to cross the blood-brain barrier was closely related to the expression level of EREG.

Key words: Cryptococcus neoformans, EREG, blood-brain barrier

CLC Number:

R379.5

ZHAO Jingyu, LIU Yishu, DING Junli, GAO Yangjie, XU Lezhen, LIAO Wanqing, FANG Wei, GU Junlin. Mechanisms of EREG incryptococcal traversal of the blood-brain barrier[J]. Chinese Journal of Mycology, 2023, 18(4): 310-314.

References

[1] ZHAO Y, LIN X. Cryptococcus neoformans: Sex, morphogenesis, and virulence[J]. Infect Genet Evol, 2021,89: 104731.DOI: 10.1016/j.meegid.2021.104731.
[2] CHOW B W, GU C. The molecular constituents of the blood-brain barrier[J]. Trends Neurosci,2015,38(10): 598-608.
[3] PULZOVA L, BHIDE M R, ANDREJ K. Pathogen translocation across the blood-brain barrier[J]. FEMS Immunol Med Microbiol,2009, 57(3): 203-213.
[4] FANG W, FA Z Z, XIE Q, et al. Complex roles of annexin A2 in host blood-brain barrier invasion by Cryptococcus neoformans[J]. CNS Neurosci Ther,2017,23(4): 291-300.
[5] SHETTY P, BARGALE A, PATIL B R, et al. Cell surface interaction of annexin A2 and galectin-3 modulates epidermal growth factor receptor signaling in Her-2 negative breast cancer cells[J]. Mol Cell Biochem, 2016,411(1-2): 221-233.
[6] GUPTA G P, NGUYEN D X, CHIANG A C, et al. Mediators of vascular remodelling co-opted for sequential steps in lung metastasis[J]. Nature, 2007,446(7137): 765-770.
[7] RIESE D J 2ND, CULLUM R L. Epiregulin: roles in normal physiology and cancer[J]. Semin Cell Dev Biol,2014,28: 49-56.DOI: 10.1016/j.semcdb.2014.03.005.
[8] PARK B J, WANNEMUEHLER K A, MARSTON B J, et al. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS[J]. AIDS,2009,23(4): 525-530.
[9] CRAWFORD C J, CORDERO R, GUAZZELLI L, et al. Exploring Cryptococcus neoformans capsule structure and assembly with a hydroxylamine-armed fluorescent probe[J]. J Biol Chem,2020,295(13): 4327-4340.
[10] TOPLIS B, BOSCH C, SCHWARTZ I S, et al. The virulence factor urease and its unexplored role in the metabolism of Cryptococcus neoformans[J]. FEMS Yeast Res, 2020,20(4):foaa031.
[11] MARUVADA R, ZHU L, PEARCE D, et al. Cryptococcus neoformans phospholipase B1 activates host cell Rac1 for traversal across the blood-brain barrier[J]. Cell Microbiol,2012,14(10): 1544-1553.
[12] HARADA M, KAMIMURA D, ARIMA Y, et al. Temporal expression of growth factors triggered by epiregulin regulates inflammation development[J]. J Immunol,2015, 194(3): 1039-1046.
[13] DRAPER B K, KOMURASAKI T, DAVIDSON M K, et al. Epiregulin is more potent than EGF or TGFalpha in promoting in vitro wound closure due to enhanced ERK/MAPK activation[J]. J Cell Biochem, 2003, 89(6): 1126-1137.
[14] TAKAHASHI M, HAYASHI K, YOSHIDA K, et al. Epiregulin as a major autocrine/paracrine factor released from ERK- and p38MAPK-activated vascular smooth muscle cells[J]. Circulation,2003,108(20): 2524-2529.
[15] CAO Y, SHI R, YANG H, et al. Epiregulin promotes osteogenic differentiation and inhibits neurogenic trans-differentiation of adipose-derived mesenchymal stem cells via MAPKs pathway[J]. Cell Biol Int,2020,44(4): 1046-1058.
[16] 孟云芳, 法振宗, 方伟,等. 隐球菌感染体外血脑屏障模型的构建与应用[J]. 中国真菌学杂志, 2015, 10(2): 92-95.
[17] VERMA V, KHOURY S, PARISIEN M, et al. The dichotomous role of epiregulin in pain[J]. Pain,2020,161(5): 1052-1064.
[18] SUNAGA N, KAIRA K. Epiregulin as a therapeutic target in non-small-cell lung cancer[J]. Lung Cancer (Auckl),2015,6: 91-98. DOI:10.2147/LCTT.S60427.
[19] SEGOVIA-MENDOZA M, DÍAZ L, GONZÁLEZ-GONZÁLEZ M E, et al. Calcitriol and its analogues enhance the antiproliferative activity of gefitinib in breast cancer cells[J]. J Steroid Biochem Mol Biol,2015,148: 122-131. DOI:10.1016/j.jsbmb.2014.12.006.